CAJ | 학술논문

目的：比较膀胱内灌注吡柔比星(THP)与丝裂霉素(CMMC)在预防浅表性膀胱癌术后复发上的疗效。方法我院于2008年2月至2010年3月接收进行尿道膀胱癌电切术后的浅表性膀胱癌肿瘤患者106例，随机分为吡柔比星组(A组)和丝裂霉素组(B组)，每组各53例。A组采用THP作为膀胱内灌注药物，B组则给予CMCC作为膀胱内灌注药物，比较两组患者3个月、6个月、12个月、24个月后的复发率，分析两组患者的不良反应。结果 A组患者3个月、6个月、12个月后的复发率分别为5.66%、9.43%、11.32%，与B组的5.66%、15.09%、20.75%比较差异无统计学意义(P>0.05)。A组24个月后的复发率(11.32%)与B组(35.85%)比较差异有统计学意义(P<0.05)。A组和B组患者经过1个月时间的治疗后不良反应发生例数分别为7例(13.21%)和10例(18.88%)，两组比较差异无统计学意义(P>0.05)。结论吡柔比星作为膀胱内灌注药物预防浅表性膀胱癌术后复发与丝裂霉素具有较好的临床疗效，可以显著降低术后复发率，也可以作为临床上的一线药物使用。
목적：비교방광내관주필유비성(THP)여사렬매소(CMMC)재예방천표성방광암술후복발상적료효。방법아원우2008년2월지2010년3월접수진행뇨도방광암전절술후적천표성방광암종류환자106례，수궤분위필유비성조(A조)화사렬매소조(B조)，매조각53례。A조채용THP작위방광내관주약물，B조칙급여CMCC작위방광내관주약물，비교량조환자3개월、6개월、12개월、24개월후적복발솔，분석량조환자적불량반응。결과 A조환자3개월、6개월、12개월후적복발솔분별위5.66%、9.43%、11.32%，여B조적5.66%、15.09%、20.75%비교차이무통계학의의(P>0.05)。A조24개월후적복발솔(11.32%)여B조(35.85%)비교차이유통계학의의(P<0.05)。A조화B조환자경과1개월시간적치료후불량반응발생례수분별위7례(13.21%)화10례(18.88%)，량조비교차이무통계학의의(P>0.05)。결론필유비성작위방광내관주약물예방천표성방광암술후복발여사렬매소구유교호적림상료효，가이현저강저술후복발솔，야가이작위림상상적일선약물사용。
Objective To observe the efficacies of intravesical pirarubicin (THP) and mitomycin (CMMC) in the prevention of recurrence of superficial bladder cancer. Methods 106 patients with superficial bladder cancer accepted urethral resection of bladder cancer in our hospital from February in 2008 to March in 2013 were enrolled in this study, which were randomly divided into Pirarubicin group (group A) and mitomycin hormone group (group B) with 53 cases in each. Patients in group A were given THP as intravesical medications, and patients in group B were treated with intravesical instillation of CMCC. We compare two groups of patients at 3 months, 6 months, 12 months, 24 months of the relapse rate respectively, and analyze the adverse reactions in two groups. Results The recurrence rates of group A at 3 months, 6 months and 12 months were 5.66%, 9.43%and 11.32%respectively, which showed no significant differences compared with those of group B (5.66%, 15.09%and 20.75%respectively, P>0.05). The recur-rence rate of group A at 24 months had significant difference from that of group B (11.32% vs 35.85%, P<0.05). There was no significant difference between the incidence of adverse reactions in group A and that in group B (13.21%vs 18.88%, P>0.05). Conclusion Pirarubicin has better clinical efficacy compared with mitomycin on the prevention of recurrence of superficial bladder cancer, which could significantly reduce the recurrence rate and could be used as a first-line drug in clinic.